The immunoregulation and clinical effect of Yupingfeng capsule combined with Seretide on patients with cough variant asthma

Abstract

Objective To detect the immunoregulation and clinical effect of Yupingfeng capsule combined with Seretide on patients with cough variant asthma (CVA). Methods CVA Patients were randomly divided into the Seretide control group (n=54) and Yupingfeng capsule combined with Seretide group (n=54). Seretide group received inhaled Seretide. Combined traditional Chinese medicine group received Seretide and Yuping Feng capsule. Two groups were treated for 12 weeks. The IL-17, IL-10 and IL-6 expression was detected by ELISA analysis. The clinic effect rate and adverse events were compared. Results After treatment, compared with the Seretide group, the expression of IL-17 (18.72±4.26 ng/ml vs. 26.17±5.58 ng/ml; t=2.462, P<0.05) and IL-6 (21.58±4.12 ng/ml vs. 30.66±6.27 ng/ml; t=2.523, P<0.05) were significantly lower in combined traditional Chinese medicine group than that in Seretide group; and IL-10 (15.56±2.74 ng/ml vs. 12.25±2.81 ng/ml; t=2.244, P<0.05) was significantly higher in combined traditional Chinese medicine group. The daytime (1.12±0.26 vs.1.42±0.33, t=2.283) and night time cough score (1.24±0.28 vs. 1.52±0.37, t=2.291) in combined traditional Chinese medicine group was significantly lower than that in Seretide group (P<0.05). The clinic effect rate (92.6% vs. 77.8%, χ2=2.438) in combined traditional Chinese medicine group was significantly higher than that in Seretide group (P=0.037). Conclusion Yupingfengcapsule combined with Seretide can decrease IL-17 expression and increase IL-10 expression to inhibit inflammatory reaction in CVA patients, and showed significantly higher clinical effect rates. Key words: Asthma; Yupingfeng capsule; Seretide; Immunoregulation; Outcome assessment